As of 2025-12-20, the EV/EBITDA ratio of Mirati Therapeutics Inc (MRTX) is -5.33. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. MRTX's latest enterprise value is 3,859.11 mil USD. MRTX's TTM EBITDA according to its financial statements is -723.54 mil USD. Dividing these 2 quantities gives us the above MRTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.4x - 15.3x | 15.1x |
| Forward P/E multiples | 17.0x - 35.2x | 21.9x |
| Fair Price | (171.86) - (154.53) | (187.12) |
| Upside | -392.8% - -363.3% | -418.8% |
| Date | EV/EBITDA |